| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Heavy metal ions (mercury, lead, copper, manganese). Emeramide is a heavy metal chelator and thiol redox antioxidant. It binds to heavy metals through its thiol (mercaptan) groups, forming stable complexes that facilitate the excretion of these metals from the body. The compound also exhibits antioxidant properties through its thiol redox activity.
|
|---|---|
| ln Vitro |
Emeramide has been shown to prevent methylmercury-induced glutathione (GSH) loss and cytotoxicity. As a thiol redox antioxidant, it can scavenge reactive oxygen species and protect cells from oxidative damage. In vitro studies demonstrate that Emeramide can chelate various heavy metals including mercury, lead, copper, and manganese, reducing their bioavailability and toxicity.
|
| ln Vivo |
In vivo studies of Emeramide are limited. As a heavy metal chelator, the compound has potential applications in treating heavy metal poisoning and reducing heavy metal burden in the body. Its antioxidant properties may also provide benefits in conditions associated with oxidative stress. However, comprehensive in vivo efficacy and safety data are not widely available in the public literature.
|
| Enzyme Assay |
In vitro chelation assays for Emeramide typically involve incubating the compound with various metal ions (e.g., Hg2+, Pb2+, Cu2+, Mn2+) in buffered solutions. The formation of metal-Emeramide complexes is monitored using UV-Vis spectroscopy, fluorescence spectroscopy, or mass spectrometry. Competitive binding studies may be performed using metal-specific indicators or chelators. The stoichiometry and stability constants of metal complexes are determined.
|
| Cell Assay |
Cellular assays for Emeramide are performed using various cell lines exposed to heavy metal toxicity. Cells are pre-treated or co-treated with Emeramide and heavy metals (e.g., methylmercury), and cell viability is assessed using MTT, LDH release, or other viability assays. Intracellular glutathione levels are measured to assess the compound's antioxidant effects. Cellular metal content can be analyzed by ICP-MS to evaluate chelation efficacy.
|
| Animal Protocol |
In vivo animal studies for Emeramide would typically involve rodent models of heavy metal poisoning. Animals would be exposed to heavy metals (e.g., mercury, lead) followed by administration of Emeramide via oral or intraperitoneal routes. Metal levels in blood, tissues, and excreta would be measured to assess chelation efficacy. Clinical signs, body weight, and organ histopathology would be evaluated to assess toxicity and therapeutic effects.
|
| ADME/Pharmacokinetics |
Emeramide has a molecular weight of 284.40 and molecular formula C12H16N2O2S2. It is soluble in DMSO (~100 mg/mL) and has low aqueous solubility (~1 mg/mL). The compound should be stored as powder at -20°C for 3 years or at 4°C for 2 years. In solvent, it is stable at -80°C for 6 months or at -20°C for 1 month. The compound is not stable in solution and should be freshly prepared.
|
| Toxicity/Toxicokinetics |
Emeramide is generally considered to have low toxicity based on its use as a heavy metal chelator. However, comprehensive toxicological data are limited. The compound contains thiol groups, which can have biological effects. Standard laboratory safety precautions should be followed when handling Emeramide. As with all chelating agents, potential mineral depletion should be considered.
|
| References |
|
| Additional Infomation |
Emeramide has been used in trials investigating the treatment of mercury poisoning.
Emeramide (BDTH2) is a thiol redox antioxidant and heavy metal chelator that has been assigned an International Nonproprietary Name (INN). It is a benzolamide derivative with intramolecular amide and mercaptan groups that can chelate various heavy metals including lead, copper, manganese, and mercury. The compound has potential applications in environmental remediation for chelating heavy metals in groundwater, wastewater, and contaminated soil, as well as potential therapeutic applications for heavy metal poisoning. Emeramide is for research use only and has not been approved for clinical use. |
| Molecular Formula |
C12H16N2O2S2
|
|---|---|
| Molecular Weight |
284.39
|
| Exact Mass |
284.065
|
| CAS # |
351994-94-0
|
| PubChem CID |
21133161
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
568.9±45.0 °C at 760 mmHg
|
| Flash Point |
297.9±28.7 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.595
|
| LogP |
1.16
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
18
|
| Complexity |
261
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JUTBAVRYDAKVGQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H16N2O2S2/c15-11(13-4-6-17)9-2-1-3-10(8-9)12(16)14-5-7-18/h1-3,8,17-18H,4-7H2,(H,13,15)(H,14,16)
|
| Chemical Name |
1-N,3-N-bis(2-sulfanylethyl)benzene-1,3-dicarboxamide
|
| Synonyms |
BDETH2; BDET; BDTH2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~351.62 mM)
H2O : ~1 mg/mL (~3.52 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5163 mL | 17.5815 mL | 35.1630 mL | |
| 5 mM | 0.7033 mL | 3.5163 mL | 7.0326 mL | |
| 10 mM | 0.3516 mL | 1.7581 mL | 3.5163 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04092205 | COMPLETED | Drug:Emeramide Other Names:NBMI Irminix |
Beta Thalassemia Major | EmeraMed | 2019-11-21 | Phase 2 |
| NCT03123692 | COMPLETED | Drug:Emeramide Drug:Placebo |
COPD COPD Bronchitis |
EmeraMed | 2017-01-01 | Phase 2 |
| NCT02486289 | COMPLETED | Drug:Emeramide Drug:Placebo |
Mercury Poisoning | EmeraMed | 2015-08 | Phase 2 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
